The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
|Articles|January 1, 2003
Playing the Waiting Game with Insurance Providers
Author(s)Inga Ellzey
Many dermatology practices are experiencing high patient demand for appointments and are expanding their services. The result frequently necessitates adding providers to the practice.
Advertisement
Advertisement
Related to this article
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
FDA Grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
3
North Immunology, Aethlon Merge to Advance NOR-101 for AD
4
Diagnostic Delays and the Psychosocial Burden of HS
5